[1]马亚鹏,李灿,边惠洁,等.PPARs对肝细胞癌的调控作用及其靶向治疗策略研究进展[J].陕西医学杂志,2026,(8):1138-1143.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.021]
　MA Yapeng,LI Can,BIAN Huijie,et al.Research progress on the regulatory roles of PPARs in hepatocellular carcinoma and targeted therapeutic strategies[J].,2026,(8):1138-1143.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.021]
点击复制

PPARs对肝细胞癌的调控作用及其靶向治疗策略研究进展

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1138-1143
栏目:
综述
出版日期:
2026-08-05

文章信息/Info

Title:
Research progress on the regulatory roles of PPARs in hepatocellular carcinoma and targeted therapeutic strategies
作者:
马亚鹏1; 李灿1; 边惠洁1; 刘泽昆1; 2
（1.空军军医大学基础医学院细胞生物学教研室 国家分子医学转化中心，陕西 西安710032；2.空军军医大学消化系肿瘤整合防治全国重点实验室，陕西 西安 710032）
Author(s):
MA Yapeng1; LI Can1; BIAN Huijie1; LIU Zekun1; 2
(1.Department of Cell Biology,School of Basic Medical Sciences,National Translational Science Center for Molecular Medicine,Air Force Medical University,Xi’an 710032,China;2.State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cance
关键词:
肝细胞癌; 过氧化物酶体增殖物激活受体; 代谢重编程; 脂代谢; 靶向治疗
Keywords:
Hepatocellular carcinoma; Peroxisome proliferator-activated receptors; Metabolic reprogramming; Lipid metabolism; Targeted therapy
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7377.2026.08.021
文献标志码:
A
摘要:
肝细胞癌（HCC）是我国致死率较高的恶性肿瘤，现有靶向及免疫治疗获益有限。过氧化物酶体增殖物激活受体（PPARs）是调控脂代谢与炎症的关键核受体，其三种亚型对HCC发挥差异化调控作用。PPARα兼具促癌与抑癌功能，其激活可增强药物敏感性；PPARβ/δ促进肝癌干细胞（LCSCs）自我更新、免疫抑制及耐药，其拮抗剂具有治疗前景；PPARγ早期抑癌、进展期促癌，但激动剂具有抗肿瘤效应。靶向PPARs的治疗策略正转向功能重塑与联合增敏，如激动剂联合靶向药、拮抗剂克服耐药等。现对PPARs家族分子对HCC的调控作用及其靶向治疗策略进行综述，以期为肝癌的靶向治疗提供科学依据。
Abstract:
Hepatocellular carcinoma (HCC) is a malignant tumor with a high mortality rate in China,and current targeted therapy and immunotherapy offer limited clinical benefits.Peroxisome proliferator-activated receptors (PPARs) are pivotal nuclear receptors governing lipid metabolism and inflammation,and their three subtypes exert differential regulatory effects on HCC.PPARα exhibits both oncogenic and tumor-suppressive functions,and its activation can improve drug sensitivity.PPARβ/δ facilitates self-renewal,immunosuppression and drug resistance of liver cancer stem cells (LCSCs),and its antagonists exhibit therapeutic potential.PPARγ suppresses tumors in early stages but promotes HCC progression in advanced stages,however,its agonists exhibit anti-tumor effects.Therapeutic strategies targeting PPARs have shifted toward functional remodeling and combined sensitization,including the combination of agonists with targeted drugs and antagonists for reversing drug resistance.This article reviews the regulatory roles of PPARs family molecules in HCC and their targeted therapeutic strategies,with the aim of providing a scientific basis for targeted therapy.

参考文献/References:

[1]孙可欣,李荔,王少明,等.2024年中国分地区恶性肿瘤流行情况分析[J].中华肿瘤杂志,2026,48(3):400-412.
[2]NAGARAJU G P,DARIYA B,KASA P,et al.Epigenetics in hepatocellular carcinoma[J].Semin Cancer Biol,2022,86(Pt 3):622-632.
[3]VOGEL A,MEYER T,SAPISOCHIN G,et al.Hepatocellular carcinoma[J].Lancet,2022,400(10360):1345-1362.
[4]FINN R S,QIN S,IKEDA M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382(20):1894-1905.
[5]周松兰,杨晓瑞,熊清,等.Nesfatin-1激活PPARγ信号通路调节脂代谢改善大鼠肥胖症实验研究[J].陕西医学杂志,2025,54(6):748-753.
[6]农金丽,杨培培,陈梓瑜,等.过氧化物酶体增殖物激活受体γ在膝骨关节炎中的作用研究进展[J].陕西医学杂志,2023,52(12):1770-1774.
[7]刘应莉,王艳荣,张秋瓒.肠道菌群-过氧化物酶体增殖物激活受体信号通路及其在代谢相关脂肪性肝病发病中的作用研究进展[J].陕西医学杂志,2021,50(9):1166-1169.
[8]ZHAO Y,TAN H,ZHANG X,et al.Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma[J].J Cell Mol Med,2024,28(5):e18042.
[9]WAGNER N,WAGNER K D.Peroxisome proliferator-activated receptors and the hallmarks of cancer[J].Cells,2022,11(15):2432.
[10]QIU Y Y,ZHANG J,ZENG F Y,et al.Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)[J].Pharmacol Res,2023,192:106786.
[11]BERTHIER A,JOHANNS M,ZUMMO F P,et al.PPARs in liver physiology[J].Biochim Biophys Acta Mol Basis Dis,2021,1867(5):166097.
[12]KANG Z,FAN R.PPARα and NCOR/SMRT corepressor network in liver metabolic regulation[J].FASEB J,2020,34(7):8796-8809.
[13]BLUNDER S,PAVEL P,MINZAGHI D,et al.PPARdelta in affected atopic dermatitis and psoriasis:A possible role in metabolic reprograming[J],Int J Mol Sci,2021,22(14):7354.
[14]QIU Y,GAN M,WANG X,et al.The global perspective on peroxisome proliferator-activated receptor γ (PPARγ) in ectopic fat deposition:A review[J].Int J Biol Macromol,2023,253(Pt 5):127042.
[15]PAN Y,LI Y,FAN H,et al.Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of hepatocellular carcinoma (HCC)[J].Biomed Pharmacother,2024,177:117089.
[16]朱书彤,赵越.PPARα在肝脏相关疾病中作用的研究进展[J].生命科学,2017,29(5):479-484.
[17]RAJESH Y,REGHUPATY S C,Mendoza R G,et al.Dissecting the balance between metabolic and oncogenic functions of astrocyte-elevated gene-1/metadherin[J].Hepatol Commun,2022,6(3):561-575.
[18]CHEN S,LING Y,YU LX,et al.4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α[J].Clin Transl Med,2021,11:e379.
[19]WANG Z,LI M,JIANG H,et al.Fructose-1,6-bisphosphatase 1 functions as a protein phosphatase to dephosphorylate histone H3 and suppresses PPARα-regulated gene transcription and tumour growth[J].Nat Cell Biol,2022;24:1655-1665.
[20]LI C,XIONG L,YANG Y,et al.Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation[J].Mol Cancer,2025,24(1):34.
[21]PAN B,ZHANG Z,YE D,et al.PPARα suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release[J].JHEP Rep,2024,7(1):101228.
[22]ZHANG Q,ZHANG Y,SUN S,et al.ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway[J].Cell Death Dis,2021,12(1):15.
[23]WU D,YANG Y,HOU Y,et al.Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1[J].Cancer Commun (Lond),2022,42(1):37-55.
[24]LI J,HUANG Q,LONG X,et al.CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways[J].J Hepatol,2015,63(6):1378-1389.
[25]DI L L,VEGLIANTE R,CICCARONE F,et al.Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53[J].Oncogene,2019,38(11):1860-1875.
[26]HAN W,WANG N,KONG R,et al.Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway[J].J Transl Med,2022,20(1):86.
[27]XU L,HAN C,LIM K,et al.Cross-talk between peroxisome proliferator-activated receptor δ and cytosolic phospholipase A2α /cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells[J].Cancer Res,2006,66(24):11859-11868.
[28]LI Z,LI H,ZHAO Z B,et al.SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδ signaling-mediated alternative activation of macrophages[J].J Exp Clin Cancer Res,2019,38(1):469.
[29]WANG Y,WANG J,LI X,et al.N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism[J].Nat Commun,2021,12(1):6314.
[30]KIM M J,CHOI Y K,PARK S Y,et al.PPARδ reprograms glutamine metabolism in sorafenib-resistant HCC[J].Mol Cancer Res,2017,15(9):1230-1242.
[31]SHOU J W,SHAW P C.Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J].Phytomedicine,2023,115:154842.
[32]SHEN B,LI A M,WAN Y Y,et al.Lack of PPARβ/δ-inactivated SGK-1 is implicated in liver carcinogenesis[J].Biomed Res Int,2020,2020:9563851.
[33]YU J,SHEN B,CHU E S,et al.Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro[J].Hepatology,2010,51(6):2008-2019.
[34]PANG X,WEI Y,ZHANG Y,et al.Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1[J].Cancer Sci,2013,104(6):672-680.
[35]XU L,XIONG L,CHEN Y,et al.IGFALS suppresses hepatocellular carcinoma progression by stabilizing PPAR-γ[J].Int Immunopharmacol,2024,143(Pt 2):113414.
[36]CAO L,SHAO Z L,LIANG H H,et al.Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression[J].Cancer Lett,2015,359(1):127-135.
[37]NING Z,GUO X,LIU X,et al.USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma[J].Nat Commun,2022,13(1):2187.
[38]TANG B,ZHU J,WANG Y,et al.Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1/L1 response[J].Adv Sci (Weinh),2023,10(2):e2203973.
[39]谭钦文,杜沅沁,黄晶晶,等.过氧化物酶体增殖物激活受体γ在肝细胞癌中作用机制研究进展[J].中华肿瘤防治杂志,2024,31(11):706-712.
[40]SHU Y,LU Y,PANG X,et al.Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4[J].Oncotarget,2016,7(47):76984-76994.
[41]HU M,ZHANG N,WANG Y Q,et al.GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARγ pathway to drive M2 macrophage polarization[J].Front Immunol,2026,17:1765930.
[42]DANIEL Y,RAUCH C,MOUTAUX L,et al.PPARγ,a key modulator of metabolic reprogramming,stemness and chemoresistance associated with retrodifferentiation in human hepatocellular carcinomas[J].Cell Death Dis,2025,16(1):831.
[43]杨亚维,袁杰.PPARα抗氧化应激作用的研究进展[J].东南大学学报(医学版),2016,35(1):147-150.
[44]PANIGRAHY D,KAIPAINEN A,HUANG S,et al.PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition[J].Proc Natl Acad Sci USA,2008,105(3):985-990.
[45]MURAKAMI K,SASAKI Y,ASAHIYAMA M,et al.Selective PPARα modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis[J].Cells,2022,11:720.
[46]ZHANG J,ZHANG W,YANG L,et al.Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARα axis through dual regulation of lipid metabolism and mitochondrial function[J].Phytomedicine.2023,109:154589.
[47]DAI M,YANG J,XIE M,et al.Inhibition of JNK signaling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate[J].Br J Pharmacol,2017,174(18):3000-3017.
[48]JARVIS M C,GRAY T J,PALMER C N.Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line[J].Oncogene,2005,24(55):8211-8215.
[49]ZAVERI N T,SATO B G,JIANG F,et al.A novel peroxisome proliferator-activated receptor delta antagonist,SR13904,has anti-proliferative activity in human cancer cells[J].Cancer Biol Ther,2009,8(13):1252-1261.
[50]MISAL S,PATIL V M,RAMAA C S,et al.Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment[J].Bioorg Chem,2025,163:108693.
[51]ADHIKARY T,BRANDT D T,KADDATZ K,et al.Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion[J].Oncogene,2013,32(44):5241-5252.
[52]BALANDARAM G,KRAMER L R,KANG B H,et al.Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice[J].Toxicology,2016,363-364:1-9.
[53]CHALASANI N,YOUNOSSA Z,LAVINE J E,et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2018,67:328-357.
[54]YANG Y,ZHAO L H,HUANG B,et al.Pioglitazone,a PPARγ agonist,inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling[J].Mol Carcinog,2015,54(12):1584-1595.
[55]CAO L Q,WANG X L,WANG Q,et al.Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway[J].Acta Pharmacol Sin,2009,30(9):1316-1322.
[56]LIU L,YANG Z,XU Y,et al.Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells[J].PLoS One,2013,8(8):e73038.
[57]SILVA-GOMEZ J A,GALICIA-MORENO M,SANDOVAL-RODRIGUEZ A,et al.Hepatocarcinogenesis prevention by pirfenidone is PPARγ mediated and involves modification of nuclear NF-kB p65/p50 ratio[J].Int J Mol Sci,2021,22(21):11360.
[58]NOJIMA H,KUBOKI S,SHINODA K,et al.Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma[J].J Hepatobiliary Pancreat Sci,2016,23(9):574-584.

相似文献/References:

[1]高延忠,王明利.CT联合MRI评估肝细胞癌病理分级可行性研究[J].陕西医学杂志,2022,51(3):375.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.026]
[2]梁 婷,斯 韬,刘湘慧,等.糖酵解及其关键限速酶在肝细胞癌中的作用研究进展[J].陕西医学杂志,2022,51(9):1171.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.030]
　LIANG Ting,SI Tao,LIU Xianghui,et al.Research progress of glycolysis and its key rate-limiting enzymes in liver cancer[J].,2022,51(8):1171.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.030]
[3]刘湘慧,斯 韬,梁 婷,等.铁死亡发生机制及其在肝细胞癌中的作用研究进展[J].陕西医学杂志,2023,52(3):354.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.025]
　LIU Xianghui,SI Tao,LIANG Ting,et al.Mechanism of ferroptosis and its role in hepatocellular carcinoma[J].,2023,52(8):354.[doi:DOI:10.3969/j.issn.1000-7377.2023.03.025]
[4]吴颖升,梁向娟,彭嘉敏,等.中性粒细胞外诱捕网在肝细胞癌转移中的作用机制及应用价值研究进展[J].陕西医学杂志,2024,(3):419.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.029]
　WU Yingsheng,LIANG Xiangjuan,PENG Jiamin,et al.Research progress on mechanism and application value of neutrophil extracellular traps in hepatocellular carcinoma metastasis[J].,2024,(8):419.[doi:DOI:10.3969/j.issn.1000-7377.2024.03.029]
[5]张振奇,贺 莉.弥散加权成像联合动态对比增强磁共振成像在肝细胞肝癌患者肝动脉化疗栓塞术后肿瘤活性检测中的应用价值[J].陕西医学杂志,2024,(6):773.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.011]
　ZHANG Zhenqi,HE Li.Application value of DWI combined with DCE-MRI in detecting tumor activity in patients with hepatocellular carcinoma after TACE[J].,2024,(8):773.[doi:DOI:10.3969/j.issn.1000-7377.2024.06.011]
[6]杨思瑜,曹春蕾,徐玉善,等.超声靶向微泡破坏技术在肝细胞癌基因治疗中的应用研究进展[J].陕西医学杂志,2024,(11):1567.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.028]
　YANG Siyu,CAO Chunlei,XU Yushan,et al.Research progress on the application of ultrasound-targeted microbubble destruction technology in gene therapy for hepatocellular carcinoma[J].,2024,(8):1567.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.028]
[7]刘光林,蒋佳伶,黄丹,等.HDAC7调控恶性肿瘤作用及机制研究进展[J].陕西医学杂志,2025,54(6):852.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.025]
　LIU Guanglin,JIANG Jialing,HUANG Dan,et al.Research progress on role and mechanism of histone deacetylase 7 in regulating malignant tumors[J].,2025,54(8):852.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.025]
[8]李禄阳,柳成刚.基于网络药理学和体外实验模型探讨淫羊藿素对肝细胞癌的抑制作用及潜在机制[J].陕西医学杂志,2025,54(12):1587.[doi:DOI:10.3969/j.issn.1000-7377.2025.12.001]
　LI Luyang,LIU Chenggang.Inhibitory effect and potential mechanism of icaritin on hepatocellular carcinoma were explored based on network pharmacology and in vitro experimental models[J].,2025,54(8):1587.[doi:DOI:10.3969/j.issn.1000-7377.2025.12.001]
[9]李乐怡,宋粉莉,刘亚珠,等.炎症微环境中肝祖细胞异常分化分子机制及致癌信号通路级联调控研究进展[J].陕西医学杂志,2026,(3):419.[doi:DOI:10.3969/j.issn.1000-7377.2026.03.022]
　LI Leyi,SONG Fenli,LIU Yazhu,et al.Research progress on molecular mechanisms of aberrant differentiation of HPCs and cascading regulation of oncogenic signaling pathways in inflammatory microenvironment[J].,2026,(8):419.[doi:DOI:10.3969/j.issn.1000-7377.2026.03.022]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82130084，82203336）；中国博士后科学基金资助项目（2022TQ0088，2024M754270）；消化系肿瘤整合防治全国重点实验室自主课题（2025GTEP008）
更新日期/Last Update: 2026-08-13